SOUTH SAN FRANCISCO, April 30 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD - News) announced today the completion of its public offering of 11,848,341 shares of its common stock, which number of shares included the underwriters’ exercise in full of their option to purchase up to 1,545,436 shares to cover over-allotments, at a public offering price of $6.33 per share. The net proceeds to the company from the sale of shares of its common stock in this offering will be approximately $70 million, after payment of underwriting discounts and commissions and estimated offering expenses. CIBC World Markets Corp. and Lazard Capital Markets LLC acted as joint book-running managers in this offering. Pacific Growth Equities, LLC, Leerink Swann & Co., Inc. and Fortis Securities LLC acted as co-managers.
